Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2146315 Target Snapshot

Nuclear receptor subfamily 1 group I member 2 · SINGLE PROTEIN · Rattus norvegicus

506Compounds
20Assays
15Approved Drugs
36.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Protein identity stays anchored to UniProt Q9R1A7. Use UniProt Q9R1A7 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q9R1A7 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Nuclear receptor subfamily 1 group I member 2 as ChEMBL target CHEMBL2146315, mapped to UniProt Q9R1A7. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Nuclear receptor subfamily 1 group I member 2
SINGLE PROTEIN · Rattus norvegicus
As of 2026-09-14
ChEMBL target ID
CHEMBL2146315
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q9R1A7
Nuclear receptor subfamily 1 group I member 2
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Nuclear receptor subfamily 1 group I member 2 is the right protein anchor across sources, using UniProt Q9R1A7 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNuclear receptor subfamily 1 group I member 2
UniProt AccessionQ9R1A7
Component TypeProtein
Sequence Length431 aa

Nuclear receptor subfamily 1 group I member 2

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Nuclear receptor subfamily 1 group I member 2, mapped to UniProt Q9R1A7. Sequence length is 431 aa.

Mapped IDQ9R1A7
Review nameNuclear receptor subfamily 1 group I member 2
OrganismRattus norvegicus
Clinical Profile

Clinical Phase Distribution

15
Approved
2
Phase III
11
Phase II
Assay Mix

Activity Type Distribution

EC5036.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL94657 8.0 EC50 10.0 Clinical
CHEMBL312862 7.05 EC50 90.0 Clinical
CHEMBL1237054 6.5 EC50 320.0 Approved
CHEMBL1200600 6.4 EC50 400.0 Approved
CHEMBL542541 6.35 EC50 450.0 Approved
CHEMBL1200617 6.17 EC50 680.0 Approved
CHEMBL1891684 5.75 EC50 1800.0 Clinical
CHEMBL98 5.6 EC50 2500.0 Approved
CHEMBL384467 5.58 EC50 2600.0 Approved
CHEMBL474260 5.55 EC50 2800.0 Clinical
Distribution

pChEMBL Value Distribution

9
5.0
4
5.5
3
6.0
1
6.5
1
7.0
0
7.5
1
8.0
0
8.5
0
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

RIMEXOLONE
CHEMBL1200617
Approved 1994
FLUOROMETHOLONE
CHEMBL1200600
Approved 1972
PLICAMYCIN
CHEMBL1237054
Approved 1970
HYDRALAZINE HYDROCHLORIDE
CHEMBL542541
Approved 1953
Assay Landscape

Assay Landscape

20
Total Assays
34
Tested Compounds
3
Assay Types
ADME — 14 assays, 34 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 14 34 5.2
Binding — 5 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 5 0
Functional — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 0

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine